Loading stock data…
GOVX
$1.16+0.06 (+5.96%)
Market ClosedLast close May 1
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GeoVax Labs, Inc. in the Healthcare sector is trading at $1.16. The stock is currently near its 52-week low of $0.96, remaining 87.4% below its 200-day moving average. Technical signals show neutral RSI of 39 and bullish MACD crossover, explaining why GOVX maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.16
Potential Upside
5%
Whystock Fair Value$1.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$77.50+6610.0%
Range$10.00 – $212.50
Fundamentals
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preve...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-515.77%
Volume
Today's trading volume
4.28M
Recent News
How The GeoVax Labs (GOVX) Story Is Shifting After The Rating Downgrade And Valuation Reset
GeoVax Labs is back in focus after its fair value estimate was cut from US$270.83 to US$190.83, a reset of roughly 30% that reflects a meaningfully lower central value estimate. Analysts now sit at a Hold rating, framing GeoVax as a mixed setup where long term potential around GEO-MVA is weighed against concerns on funding, timelines, and near term catalysts. In the sections that follow, you will see how this updated valuation call fits into the evolving GeoVax story and what signals to watch...
Why The GeoVax Labs (GOVX) Story Is Shifting As Valuation Holds And Risks Rise
The latest update keeps GeoVax Labs' fair value estimate steady at US$270.83, signaling no change to the headline price target in this round of analysis. That stability comes as analysts shift to a Hold stance, weighing the company’s funding needs and execution risk against the longer term potential reflected in the current valuation work. Read on to see what is driving this evolving narrative and how you can track the key data points from here. Analyst Price Targets don't always capture the...
How The Story On GeoVax Labs (GOVX) Is Shifting Toward Execution Risk And Funding Constraints
The updated fair value estimate for GeoVax Labs holds steady at about US$270.83 per share, signaling no change to the central price target in the current model. That stability comes as analysts adopt a more cautious tone, with enthusiasm around the GEO-MVA program now balanced by concerns over execution, funding, and a thinner set of near term catalysts. As you read on, you will see how this evolving narrative might shape your view of the stock over time and what to watch next. Analyst Price...
Siga Technologies Q4 Earnings Call Highlights
Siga Technologies (NASDAQ:SIGA) reported 2025 results and provided a business update focused on its role in global smallpox preparedness, highlighting product deliveries under its current U.S. government contract, ongoing development programs, and expectations around a European regulatory review for
Shopify, eBay upgraded: Wall Street's top analyst calls
Shopify, eBay upgraded: Wall Street's top analyst calls